| Identification | Back Directory | [Name]
KY-02327
(KY02327) | [CAS]
2093407-25-9 | [Synonyms]
KY-02327
KY-02327
(KY02327)
Ethyl 5-hydroxy-1-(2-oxo-2-((2-(piperidin-1-yl)ethyl)amino)ethyl)-1H-indole-2-carboxylate
1H-Indole-2-carboxylic acid, 5-hydroxy-1-[2-oxo-2-[[2-(1-piperidinyl)ethyl]amino]ethyl]-, ethyl ester
Wnt,KY-02327,CXXC5,osteoblast,differentiation,inhibit,anti-osteoporosis,Dishevelled,KY 02327,bone,Inhibitor,anabolic,KY02327 | [Molecular Formula]
C20H27N3O4 | [MDL Number]
MFCD34567263 | [MOL File]
2093407-25-9.mol | [Molecular Weight]
373.45 |
| Chemical Properties | Back Directory | [Boiling point ]
627.2±55.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (267.77 mM; Need ultrasonic) | [form ]
Solid | [pka]
9.53±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
KY-02327, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation[1]. | [in vivo]
KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) successfully rescues bone loss in the ovariectomized (OVX) mouse model[1]. | Animal Model: | 8-week-old female BL6 mice (ovariectomized (OVX)-induced osteoporosis model mice)[1] | | Dosage: | 20 mg/kg | | Administration: | P.o.; administered for 5 sequential days per week for 4 weeks | | Result: | Newly formed bones which labeled with calcein were decreased in the femur of vehicle‐treated OVX mice.
|
| [storage]
Store at -20°C | [References]
[1] Kim HY, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387. DOI:10.15252/emmm.201505714 |
|
|